The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Rep. Mike Collins (R-Ga.) heavily criticized statements made by the Right Rev. Mariann Budde on Tuesday at the inaugural ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...